CSI Market
Sign In | Register

Regencell Bioscience Holdings Limited (RGC) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access RGC Annual Cash Flow →
This cash flow overview for Regencell Bioscience Holdings Limited spans from Jun 30 2024 to Jun 30 2025, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2025)
12 Months 		0 0 0 (Jun 30 2024)
Operating Activities
Income-3.58
Depreciation & amortization0.08
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventory for Long-term Contracts or Programs0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation0.24
Proceeds from Equity Method Investment, Dividends or Distributions0.00
Financial Instruments and Foreign Currency Transaction0.00
Gain Loss On Disposal And Impairment Of Operating Assets-
Equity Method Investment Other Than Temporary Impairment-
Equity In Earnings Of Nonconsolidated Entities And Other-
Gain On Business Interruption Insurance Recovery-
Equityin Earnings of Nonconsolidated Entities-
Derivative Instruments Gain Loss Recognized In Income Ineffective Portion And Amount Excluded From Effectiveness Testing Net-
Increase Decreasein Noncash Rent Expense-
Payments Received for Capital Expenditures-
Noncash Rent Expense-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Receivables0.00
Increase (Decrease) in Due to Other Related Parties-0.01
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities0.22
Deferred Revenue and Customer Advances and Deposits0.00
Prepaid Expense and Other Assets0.15
Other Working Capital-0.35
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-3.11
Investing Activities
Capital Expenditures-0.15
Sale of Capital Items0.00
Short-term Investments Proceeds2.84
Short-term Investments Acq.0.00
Real Estate Investments0.00
Equity Method Investment Net Sales Proceeds-
Changes In Other Long Term Assets-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Payments to Acquire Equity Method Investments0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities2.69
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Subsidiaries Senior Long Term Debt-
Payment Of Debt Discount-
Cash Used To Purchase Treasury Shares And Other-
Proceeds from Issuance of Senior Longterm Debt-
Cash Paid For Tax Withholdings And Other-
Proceeds From Issuance of Senior Longterm Debt-
Proceeds From Issuance of Senior Longterm Debt-
Lease Financing Arrangements Landlord Contribution-
Repayments of Senior Debt-
Repayments of Senior Debt-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.00
Effect of exchange rate on cash flow-0.11
Discontinued operations0.00
Free Cash Flow-3.27
Total Cash Flow-0.54
4 historic quarters locked

Sign in to unlock the full Regencell Bioscience Holdings Limited cash flow history.

Sign In Create Free Account

About Regencell Bioscience Holdings Ltd Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 20-F filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001213900-25-104686

Figures are derived from filed reports and may be restated. Historical data is subject to revision.